Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Global Markets Direct Report Coverage | 10 | 1 |
| Ocular Hypertension Overview | 11 | 1 |
| Therapeutics Development | 12 | 2 |
| Pipeline Products for Ocular Hypertension Overview | 12 | 1 |
| Pipeline Products for Ocular Hypertension Comparative Analysis | 13 | 1 |
| Ocular Hypertension Therapeutics under Development by Companies | 14 | 2 |
| Ocular Hypertension Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
| Ocular Hypertension Pipeline Products Glance | 17 | 3 |
| Late Stage Products | 17 | 1 |
| Clinical Stage Products | 18 | 1 |
| Early Stage Products | 19 | 1 |
| Ocular Hypertension Products under Development by Companies | 20 | 2 |
| Ocular Hypertension Products under Investigation by Universities/Institutes | 22 | 1 |
| Ocular Hypertension Companies Involved in Therapeutics Development | 23 | 23 |
| Aerie Pharmaceuticals, Inc. | 23 | 1 |
| Allergan Plc | 24 | 1 |
| Amakem NV | 25 | 1 |
| Bausch &Lomb Incorporated | 26 | 1 |
| Can-Fite BioPharma Ltd. | 27 | 1 |
| D. Western Therapeutics Institute, Inc. | 28 | 1 |
| F. Hoffmann-La Roche Ltd. | 29 | 1 |
| Inotek Pharmaceuticals Corporation | 30 | 1 |
| Ironwood Pharmaceuticals, Inc. | 31 | 1 |
| Kowa Company, Ltd. | 32 | 1 |
| Laboratoires Thea S.A. | 33 | 1 |
| Laboratorios Sophia S.A. de C.V. | 34 | 1 |
| Lee's Pharmaceutical Holdings Limited | 35 | 1 |
| Lexicon Pharmaceuticals, Inc. | 36 | 1 |
| NicOx S.A. | 37 | 1 |
| Ocular Therapeutix, Inc. | 38 | 1 |
| Otsuka Holdings Co., Ltd. | 39 | 1 |
| pSivida Corp. | 40 | 1 |
| Sanofi | 41 | 1 |
| Santen Pharmaceutical Co., Ltd. | 42 | 1 |
| Senju Pharmaceutical Co., Ltd. | 43 | 1 |
| Sylentis S.A.U. | 44 | 1 |
| ViSci Ltd. | 45 | 1 |
| Ocular Hypertension Therapeutics Assessment | 46 | 10 |
| Assessment by Monotherapy Products | 46 | 1 |
| Assessment by Combination Products | 47 | 1 |
| Assessment by Target | 48 | 2 |
| Assessment by Mechanism of Action | 50 | 2 |
| Assessment by Route of Administration | 52 | 2 |
| Assessment by Molecule Type | 54 | 2 |
| Drug Profiles | 56 | 66 |
| (bimatoprost + brimonidine tartarate + timolol maleate) Drug Profile | 56 | 1 |
| (bimatoprost + timolol maleate) Drug Profile | 57 | 1 |
| (carteolol hydrochloride + latanoprost) Drug Profile | 58 | 1 |
| (latanoprost + netarsudil mesylate) Drug Profile | 59 | 2 |
| (latanoprost + timolol maleate) Drug Profile | 61 | 1 |
| (latanoprost + trabodenoson) Drug Profile | 62 | 1 |
| AMA-0076 Drug Profile | 63 | 2 |
| bamosiran Drug Profile | 65 | 3 |
| bimatoprost Drug Profile | 68 | 1 |
| bimatoprost SR Drug Profile | 69 | 2 |
| DE-117 Drug Profile | 71 | 1 |
| Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension Drug Profile | 72 | 1 |
| H-1129 Drug Profile | 73 | 1 |
| IWP-953 Drug Profile | 74 | 1 |
| latanoprost Drug Profile | 75 | 1 |
| latanoprost Drug Profile | 76 | 2 |
| latanoprost SR Drug Profile | 78 | 1 |
| latanoprost SR Drug Profile | 79 | 1 |
| latanoprost SR Drug Profile | 80 | 1 |
| latanoprostene bunod Drug Profile | 81 | 4 |
| levobetaxolol hydrochloride Drug Profile | 85 | 1 |
| LX-7101 Drug Profile | 86 | 1 |
| MGV-354 Drug Profile | 87 | 1 |
| NCX-1653 Drug Profile | 88 | 1 |
| NCX-470 Drug Profile | 89 | 1 |
| NCX-667 Drug Profile | 90 | 1 |
| netarsudil mesylate Drug Profile | 91 | 5 |
| OPA-6566 Drug Profile | 96 | 1 |
| piclidenoson Drug Profile | 97 | 9 |
| PRO-067 Drug Profile | 106 | 1 |
| RG-4929 Drug Profile | 107 | 1 |
| ripasudil Drug Profile | 108 | 2 |
| RO-5093151 Drug Profile | 110 | 1 |
| SAR-366234 Drug Profile | 111 | 1 |
| Sepetaprost Drug Profile | 112 | 1 |
| SNJ-1656 Drug Profile | 113 | 2 |
| trabodenoson Drug Profile | 115 | 3 |
| travoprost SR Drug Profile | 118 | 2 |
| travoprost XR Drug Profile | 120 | 2 |
| Ocular Hypertension Dormant Projects | 122 | 2 |
| Ocular Hypertension Discontinued Products | 124 | 1 |
| Ocular Hypertension Product Development Milestones | 125 | 11 |
| Featured News &Press Releases | 125 | 1 |
| Jun 16, 2016: Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa (netarsudil ophthalmic solution) 0.02% | 125 | 1 |
| May 05, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% | 125 | 1 |
| Apr 27, 2016: Ocular Therapeutix Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension | 126 | 1 |
| Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting | 126 | 1 |
| Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension | 127 | 1 |
| Mar 28, 2016: Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% | 128 | 1 |
| Mar 17, 2016: Aerie Pharmaceuticals Reports Update on Positive Safety Results for Rhopressa QD (netarsudil ophthalmic solution) 0.02% | 128 | 1 |
| Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting | 129 | 1 |
| Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week | 130 | 1 |
| Feb 17, 2016: Aerie Pharmaceuticals Reports Positive Rhopressa QD (netarsudil ophthalmic solution) 0.02% 12 Month Interim Safety Results for Rocket 2 | 131 | 1 |
| Feb 16, 2016: Ocular Therapeutix Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension | 131 | 1 |
| Oct 22, 2015: Ocular Therapeutix Reports on Topline Results of Phase 2b Glaucoma Clinical Trial | 132 | 2 |
| Oct 01, 2015: New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension | 134 | 1 |
| Sep 24, 2015: Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa | 134 | 1 |
| Sep 21, 2015: Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of Roclatan | 135 | 1 |
| Appendix | 136 | 2 |
| Methodology | 136 | 1 |
| Coverage | 136 | 1 |
| Secondary Research | 136 | 1 |
| Primary Research | 136 | 1 |
| Expert Panel Validation | 136 | 1 |
| Contact Us | 136 | 1 |
| Disclaimer | 137 | 1 |